

Out-come based planning and patient (customer) centricity approach. Thorough team contributor with strong organizational capabilities and managing multiple priorities with a positive attitude. Combines strategic thinking with hands-on experience to deliver impactful solutions and enhance organizational performance and willingness to take on added responsibilities to meet team goals and work aspiration.
· Lead and hold the accountability for the execution of Medical Affairs Plans to support Product Brand objectives.
· Successful to establish Clinical Operation Unit in Vietnam to support Regional Clinical Operation activity including sites and investigators identifications and follow up with Authorities.
· Maintain scientific network with key thought leaders to develop strategic Partnerships
· Provide Medical Affairs Expert through medical input for important commercial meetings, regulatory strategy and company crisis management.
· Manage and be responsible for regulatory submissions and compliance issues, including drug registration, drug reimbursement as well as other related licenses.
· Manage key stakeholder relationships to promote a sensible regulatory environment in support of business objectives and priorities.
· Manage and be responsible for regulatory submissions and compliance issues, including drug registration, drug reimbursement as well as other related licenses.
· Manage key stakeholder relationships to promote a sensible regulatory environment in support of business objectives and priorities.
Coaching and Mentoring
Team Leadership
Customer Focus
Innovation management
Community involvement
Self Motivation
Adaptability and Flexibility
Strategic Planning
Oncology at Roche
1.Successfully listed Vietnam into Clinical Study Map for Roche/Gennetech with the 1st ever phase 3 study in 2013 (Herceptin SC and Mabthera SC). Total 9 studies conducted in Vietnam within 10 years.
- Established procedure for HER2 testing, EGFR and ALK testing to support patient access and reimbursement.
- Launched successfully number of Oncology products: Mabthera SC in NHL, Herceptin SC, Kadcylar, Perjeta in BC, Tecentriq and Alecensa in LC.
- Early access for Polivy in relapse NHL
- Public Awareness on BC screening: We Care For Her/Joining Hand for Her (a foundation to enlisting BC screening package for reimbursement)
Specialty at Boehringer Ingelheim
- Attracting number of early phases clinical studies conducted in Vietnam: CatC in Bronchitis, EASi in HF, Spesolimab in HS and GPP
- Driving to obtain early access approval for Spevigo in GPP patients in Vietnam.
Gardening
Travelling
Photograph